Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

• Main Authors: Jonathan I. Silverberg (Author), Andreas Wollenberg (Author), Linda Stein Gold (Author), James Del Rosso (Author), Gil Yosipovitch (Author), Peter Lio (Author), Jose-Manuel Carrascosa (Author), Gaia Gallo (Author), Yuxin Ding (Author), Zhenhui Xu (Author), Marta Casillas (Author), Evangeline Pierce (Author), Helena Agell (Author), Sonja Ständer (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Lebrikizumab is a novel monoclonal antibody with established efficacy in patients with moderate-to-severe atopic dermatitis (AD) in multiple Phase 3 trials. One of the ultimate treatment goals for patients with moderate-to-severe AD is to achieve stable disease control without...